Sponsor
Biogen
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Biogen appears in 345 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
60 shownPregnancy Exposure Registry for Vumerity (Diroximel Fumarate)NCT05658497 · lead sponsor · 2023-10-27
RECRUITINGA Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)NCT07483632 · lead sponsor · 2026-11-16
NOT_YET_RECRUITINGA Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)NCT05767736 · lead sponsor · 2024-06-08
ACTIVE_NOT_RECRUITINGA Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) TreatmentsNCT06127095 · lead sponsor · 2023-11-24
COMPLETEDA Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)NCT05798520 · lead sponsor · 2023-07-25
COMPLETEDA Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)NCT05925049 · lead sponsor · 2023-06-30
ACTIVE_NOT_RECRUITINGA Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in ChinaNCT05658484 · lead sponsor · 2023-06-09
COMPLETEDZuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)NCT05655507 · lead sponsor · 2023-04-19
COMPLETEDA Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) ParticipantsNCT05701423 · lead sponsor · 2023-02-08
TERMINATEDA Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)NCT05532163 · lead sponsor · 2023-01-23
TERMINATEDA Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating ScaleNCT05418673 · lead sponsor · 2022-08-26
TERMINATEDA Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of AgeNCT05399888 · lead sponsor · 2022-08-24
ACTIVE_NOT_RECRUITINGA Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's DiseaseNCT05310071 · lead sponsor · 2022-06-02
TERMINATEDA Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple SclerosisNCT05265728 · lead sponsor · 2022-04-26
TERMINATEDA Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80NCT05348785 · lead sponsor · 2022-04-19
COMPLETEDA Study to Explore Association Patterns Between Digital Outcome Assessments From the Konectom™ Platform and Magnetic Resonance Imaging (MRI) Measures of Brain Tissue DamageNCT05106465 · lead sponsor · 2021-12-15
COMPLETEDExploring Diroximel Fumarate Real-world Experience in Canada and IsraelNCT04948606 · lead sponsor · 2021-12-09
TERMINATEDAn Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the USNCT05097131 · lead sponsor · 2021-11-18
TERMINATEDA Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of Multiple Sclerosis (RMS)NCT05083923 · lead sponsor · 2021-11-18
COMPLETEDA Study for Tysabri Participant PreferenceNCT05304520 · lead sponsor · 2021-10-12
COMPLETEDA Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesNCT05688436 · lead sponsor · 2021-09-24
ACTIVE_NOT_RECRUITINGSevere Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination StudyNCT05197699 · lead sponsor · 2021-07-01
TERMINATEDStudy to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)NCT04079088 · lead sponsor · 2021-06-30
WITHDRAWNStudy to Investigate Pregnancy Outcomes in Female Participants Exposed to Subcutaneous (SC) Peginterferon Beta-1a and Intramuscular (IM) Interferon Beta-1a Reported in a German Participant Support ProgramNCT04655222 · lead sponsor · 2021-04-30
COMPLETEDReal World Analysis on Lymphocyte Reconstitution After Lymphopenia in Participants Treated by TecfideraNCT04756687 · lead sponsor · 2021-03-10
COMPLETEDStudy of Diroximel Fumarate in the Real-World SettingNCT04746976 · lead sponsor · 2021-03-01
TERMINATEDMS PATHS COVID-19 Questionnaire Data Linkage Sub-StudyNCT05058729 · lead sponsor · 2020-12-07
COMPLETEDA Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive DisorderNCT04476030 · lead sponsor · 2020-11-09
COMPLETEDValidation of DigiCog and Konectom Tools to Support Digitalized Clinical Assessment in Multiple SclerosisNCT04756700 · lead sponsor · 2020-10-12
COMPLETEDPharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic PolyneuropathyNCT04106050 · lead sponsor · 2020-09-30
WITHDRAWNA Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic MutationNCT04494256 · lead sponsor · 2020-09-28
TERMINATEDA Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)NCT04442503 · lead sponsor · 2020-06-08
COMPLETEDA Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)NCT04442490 · lead sponsor · 2020-05-12
COMPLETEDA Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205NCT04241068 · lead sponsor · 2020-03-02
TERMINATEDA Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple SclerosisNCT03958877 · lead sponsor · 2019-10-18
ACTIVE_NOT_RECRUITINGDimethyl Fumarate (DMF, Tecfidera®) Persistence in RR-MS Patients Included in the French Patient Support Program OroSEPNCT04221191 · lead sponsor · 2019-08-19
COMPLETEDA Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive DisorderNCT04007367 · lead sponsor · 2019-08-06
TERMINATEDStudy to Evaluate DNL151 in Subjects With Parkinson's DiseaseNCT04056689 · lead sponsor · 2019-07-23
COMPLETEDA Real-world Study of Imraldi® UseNCT04089514 · lead sponsor · 2019-06-30
COMPLETEDFeasibility of the Multiple Sclerosis Performance Test in Participants With Multiple SclerosisNCT03926637 · lead sponsor · 2019-06-17
TERMINATEDQuantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHSNCT04145284 · lead sponsor · 2019-04-30
COMPLETEDStudy to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric ParticipantsNCT03870763 · lead sponsor · 2019-03-19
TERMINATEDA Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's DiseaseNCT03716570 · lead sponsor · 2019-03-12
TERMINATEDA Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)NCT03864614 · lead sponsor · 2019-02-27
COMPLETEDA Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and InsomniaNCT03771664 · lead sponsor · 2019-02-04
TERMINATEDTOPIK Study: A Study to Report Progressive Multifocal Leukoencephalopathy and Other Serious Opportunistic Infections in Natalizumab Treated ParticipantsNCT05236777 · lead sponsor · 2019-01-01
COMPLETEDA Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging AbnormalitiesNCT03639987 · lead sponsor · 2018-12-20
TERMINATEDA Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab AdministrationNCT03689972 · lead sponsor · 2018-11-27
COMPLETEDA Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive DisorderNCT03672175 · lead sponsor · 2018-11-19
COMPLETEDA Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)NCT03745820 · lead sponsor · 2018-11-15
COMPLETEDA Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 in Adults With C9ORF72-Associated Amyotrophic Lateral SclerosisNCT03626012 · lead sponsor · 2018-09-10
COMPLETEDA Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive EpisodeNCT03692910 · lead sponsor · 2018-08-23
COMPLETEDOne-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort StudyNCT03662919 · lead sponsor · 2018-07-02
COMPLETEDEfficacy and Safety Study of BIIB074 in Participants With Small Fiber NeuropathyNCT03339336 · lead sponsor · 2018-05-31
TERMINATEDPhase 2 Study of BIIB092 in Participants With Early Alzheimer's DiseaseNCT03352557 · lead sponsor · 2018-05-03
TERMINATEDEvaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's DiseaseNCT03318523 · lead sponsor · 2018-01-10
TERMINATEDA Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIXNCT03366337 · lead sponsor · 2017-12-26
COMPLETEDMS PATHS Normative Sub-StudyNCT02996084 · lead sponsor · 2017-12-12
COMPLETEDA Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple SclerosisNCT03347370 · lead sponsor · 2017-11-27
COMPLETEDEfficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)NCT03222973 · lead sponsor · 2017-11-15
TERMINATEDSponsor roles
lead sponsor261
collaborator84
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.